Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Investor Day (February 2021)
33 slides from Sanofi Sa's investor day presentation, Feb 5, 2021
Slide 1: CMD21 Play to Win
CMD21 February 5, 2021 Play to Win
Slide 2: Forward looking statements
Forward looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlyin
Slide 3: Agenda CMD21 - part 1
Agenda CMD21 - part 1 Driving growth with strategic choices Paul Hudson CEO Focus on transformative therapies Dietmar Berger Head of Development, CMO Olivier Charmeil Head of General Medicines Leveraging our DNA to build our future Alexandre de Germay Head of Global CV & EP Franchise Julie van Ongev
Slide 4: Driving growth with strategic choices
Driving growth with strategic choices Paul Hudson Chief Executive Officer
Slide 5: Play to Win: Our six-year plan – ahead of schedule
Play to Win: Our six-year plan – ahead of schedule 2020-2022 2023-2025+ • Refocus with decisive actions • Transformative launches • Growth through winning assets • Agile and efficient resource deployment • Margin expansion • Leading R&D productivity 5
Slide 6: Our key growth drivers are delivering
Our key growth drivers are delivering Dupixent® Vaccines Pipeline Maximize patient benefits Expected mid-to-high single-digit Prioritize and accelerate with ambition to achieve >€10 growth(1), through differentiated portfolio of potentially billion peak sales across type 2 products, market expansion
Slide 7: Clear capital allocation priorities to strengthen R&D
Clear capital allocation priorities to strengthen R&D (1) (1) Provides Tailored Adds platform of Covalency™ Adds proprietary Offers access to M&A SynthorinsTM in oncology and platform and clinical pipeline of BTKi’s next generation of cell-based cancer KY1005, a human mAb targeting key immunology in
Slide 8: EUROAPI to become a leading European API company
EUROAPI to become a leading European company providing active pharmaceutical ingredients New industry champion with six European manufacturing sites • Expected sales of ~€1 bn by 2022, world #2 • ~3,200 employees - headquartered in France • CEO appointed – Karl Rotthier, with ~30 years international
Slide 9: BOI margin up 120bps in 2020 tracking toward 2022 target
BOI margin up 120bps in 2020 tracking toward 2022 target Sanofi expected BOI margin evolution >32% Expected margin drivers to reach 2022 goal • Sales growth 30% • Improved mix 27.1% + • Smart spending • Resource reallocation 25.9% • Operational excellence • Launch costs 2019 2020 … 2022e 2025e - • A
Slide 10: Driving growth with strategic choices
Driving growth with strategic choices Company Sales by GBU in 2020 €11.0bn €4.4bn +22.4% -1.9% €36.0bn €6.0bn +3.3% €14.7bn +8.8% -7.6% Specialty Care Vaccines General Medicines Consumer Healthcare Dupixent® Differentiated flu Core brands & markets Standalone model MS / Neurology / I&I Pediatric com
Slide 11: Focus on transformative therapies – status update
Focus on transformative therapies – status update Dietmar Berger Chief Medical Officer
Slide 12: Status update of our late-stage priority assets
Status update of our late-stage priority assets Asset Key progress Planned initial submission(1) 3 new indications announced and in Phase 3; AD EU 6-11 years Dupixent®(2) approval; asthma 6-11 years pivotal results Launched 2L/3L mBC Phase 3 (AMEERA-3) data expected in H1 2021; Amcenestrant 1L mBC c
Slide 13: Fitusiran pivotal trial dosing resumed
Fitusiran pivotal trial dosing resumed – new dose and regimen potentially strengthening target profile • Fitusiran dosing resumed(1) in January, Fitusiran has the potential to transform less than 3 months following voluntary pause the treatment of Hemophilia • Amendments to protocol to maintain anti
Slide 14: Venglustat – a central regulator of GSL pathway
Venglustat – a central regulator of GSL pathway, potentially transformative across multiple rare diseases Venglustat • Next-generation oral, brain-penetrating GCS inhibitor Inhibits GCS • PoC achieved in Gaucher Type 3 and Fabry Diseases Associated diseases • Development in Parkinson’s Disease halte
Slide 15: Leveraging our DNA to build our future
Leveraging our DNA to build our future General Medicines Olivier Charmeil Head of General Medicines Alexandre de Germay Head of Global CV & EP Franchise
Slide 16: Actively managing an accretive and resilient business
Actively managing an accretive(1) and resilient business Stabilize sales and maintain current BOI ratio(2) GenMed sales(3) Simplification • Volume & price Illustrative of portfolio • 2018-2020 decline mostly driven by price vs. stable volumes • Portfolio remains critical for chronic disease ~40% Dig
Slide 17: Volumes of off-patent EP stabilizing with core assets in demand
Overall, volumes of off-patent EP stabilizing with core assets still benefiting from strong demand in key EMs Sanofi EP non-core volume stabilization Lovenox® & Plavix®: Capturing class market growth at low price level opportunities in Emerging Markets and China Clopidogrel bisulfate 115 Standard of
Slide 18: Cardiometabolic diseases: Differentiated growth drivers
Cardiometabolic diseases: Differentiated growth drivers to address patient needs alirocumab Insulin gargine U300 Insulin glargine U100 + lixisenatide Patent ✔ ✔ ✔ ✔ • Only PCSK9i associated • Only AAD to reduce CV • Anticipated further differentiation vs. • Anticipated differentiation vs. with reduc
Slide 19: Critical enablers to transform GenMed
Critical enablers to transform GenMed Focus on 13 key markets Interacting digitally with our customers Expected sales distribution in 2025 HCP interactions 2020 status • Digital transformation (accelerated by Adapting go-to- 30% market in non-key COVID) markets 70% • ePermission for ~60% of our targ
Slide 20: Executing on streamlining the tail ahead of target
Executing on streamlining the tail ahead of target Simplification drives COGS improvement ~300 ~-65% ~180 Number of branded product families ~100 Long tail 2018 2020 2025e ~€1.5bn cash proceeds expected in 2019-2025 20
Slide 21: General Medicines: Accretive and resilient contributor to group BOI margin
General Medicines: Accretive and resilient contributor to group BOI margin Core assets with differentiated profile Focus on key markets COGS improvement Digital Go-to-Market Market leadership positions and productivity in China and key EM 21
Slide 22: Unlocking value
Unlocking value Consumer Healthcare Julie Van Ongevalle Head of Consumer Healthcare Josephine Fubara Chief Science Officer, CHC
Slide 23: Sanofi's Consumer Healthcare 'Play to Win' strategy
Sanofi’s Consumer Healthcare ‘Play to Win’ strategy Focus on growth Lead with innovation Accelerate efficiency Reinvent how we work Brand prioritization Reignite Simplify portfolio Become a fast-moving innovation engine consumer healthcare company Acceleration in U.S. Deliver switches Optimize go-to
Slide 24: Global OTC market is growing at 4.5% CAGR 2020-2025
Global OTC market is growing at 4.5% CAGR 2020-2025(1) Global OTC Market CAGR 2020-2025(1) €130bn +4.4%(2) Body Pain +6.4% Probiotics +6.4% Liver Care +5.4% Bone Health +5.3% Our priorities €51bn +5.9%(2) Allergy +4.7% Mental Wellness +4.6% Sleep, Fatigue, Stress General Pain +4.1% Physical Wellness
Slide 25: Growth driven by local, regional and global love brands
Growth driven by local, regional and global love brands #3 #1 #3 Allergy General Pain Body Pain Source – Internal data (Sinergi MAT Sep 2020) 25 Numbers above represent global ranking in value in these categories
Slide 26: Strengthening our presence in Mental Wellness
Strengthening our presence in Mental Wellness • Mental Wellness expected to grow 4.6% over next 5 years • Sleep represents ~40% of Mental Wellness • Double-digit growth in 2020 enhanced by COVID-19 • Expected to grow 5.3% over the next 5 years • Established local positions in: • U.S. • Europe • Japa
Slide 27: Standalone CHC on track to be in place end of 2022
Standalone CHC on track to be in place end of 2022 Implementation ongoing Benefits to growth • Consumer and data at the core of every ✔• Design and overall planning complete business decision ✔• Relevant social processes on schedule • Reignite our innovation engine and reduce time-to-market by aroun
Slide 28: First-in-class U.S. switches with €1bn U.S. sales potential
First-in-class U.S. switches with €1bn U.S. sales potential Cialis® • >30m(1) U.S. men suffer from erectile dysfunction (ED) Label comprehension, self- Expected selection, human factors launch • U.S market leader as Rx product (Lilly) • Anticipate being the first OTC treatment for ED (PDE5i) Program
Slide 29: Invest in brands and geographies of focus for best-in-market growth
Invest in brands and geographies of focus for best-in- market growth in 2024/2025 Above market growth • Ambition for best-in-market growth with Switches switches from 2024/2025 Priorities • Grow priority brands above market growth as early as 2022 in key geographies Other(1) • Supported by consumer
Slide 30: Our people ambitions
Our people ambitions Natalie Bickford Chief People Officer
Slide 31: Our business imperative
Our business imperative What we need to successfully deliver the ‘Play to Win’ strategy A significant culture shift The acquisition/ towards the PTW Stretch development of new skills behaviors and leadership capability Act for Take A simplified and patients and Diversity & inclusion to action more a
Slide 32: Our 'Play to Win' 2025 people ambitions
Our ‘Play to Win’ 2025 people ambitions Healthy organization Purposeful experience Winning culture Diversity edge Sanofi is an agile and Employees own their Our culture allows Our business out- competitive organization career journey, stretching our people to thrive performs through our meeting pati
Slide 33: Q&A session
Q&A session Paul Hudson Natalie Bickford CEO Chief People Officer Olivier Charmeil Jean-Baptiste de Chatillon Head of General Medicines CFO Julie van Ongevalle John Reed Head of Consumer Healthcare Head of R&D Arnaud Robert Dietmar Berger Chief Digital Officer Head of Development, CMO Josephine Fuba